Galapagos enters into discovery collaboration with Idenix for infectious disease programs
Galapagos NV announced that it has entered into a collaboration with Idenix Pharmaceuticals, Inc. on selected hepatitis and HIV infectious disease programs. Pursuant to the collaboration, Galapagos' service division BioFocus will supply its proprietary SoftFocus® chemical compound collections to Idenix and provide expertise in the design and synthesis of biologically-directed compound collections. In addition, BioFocus will provide hit-to-lead and lead optimisation services. The entire discovery contract collaboration is worth up to $2.5 million over two years.
This arrangement represents Galapagos' first collaboration with Idenix. Under the terms of the agreement, Galapagos will receive undisclosed technology access fees for SoftFocus® collections, as well as a fee component for medicinal chemistry services plus success payments upon realization of certain objectives relating to the identification of pre-clinical candidates.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications - Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
AnaSpec and UW TechTransfer Sign Licensing Agreement for Protein Tyrosine Phosphatases
